首页> 外文期刊>Journal of Clinical Pathology >The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.
【24h】

The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.

机译:骨髓类胰蛋白酶的阳性紧密小圆细胞浸润(TROCI-BM):一种新的组织病理学发现,需要应用谱系特异性标记。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Compact tryptase-positive round cell infiltrates of the bone marrow (TROCI-BM) are very rare histopathological findings and may pose challenging problems with regard to the cell type involved (either mast cells or basophilic granulocytes) and the exact diagnosis. METHODS: A selected panel of immunohistochemical markers against mast cell and basophil related antigens, including CD25, CD34, CD117/Kit, and the 2D7 antigen (which is found only in basophilic granulocytes) on a total of 410 routinely processed bone marrow biopsy specimens (including 88 cases of systemic mastocytosis (SM), 20 cases of chronic myeloid leukaemia (CML), 92 cases of myeloid neoplasms other than CML, and 210 controls with normal/reactive bone marrows). RESULTS: In total, 17 cases with TROCI-BM could be identified: 11 SM (including two cases of well-differentiated SM and two mast cell leukaemias; MCL), 2 myelomastocytic leukaemia (MML), 2 CML with excess of basophils (secondary basophilic leukaemia (CMLba)), and 2 tryptase positive acute myeloid leukaemia (AML). Regarding the cell types involved, TROCI-BM cells were found to express CD117/Kit in all cases of SM and MCL. In MML and tryptase postitive AML, TROCI-BM cells were found to coexpress CD34 and Kit. The basophil specific antigen 2D7 was only detected in CD34/Kit negative TROCI-BM cells in two patients with CMLba. The activating point mutation D816V was detected in 8/11 patients with SM but not in any of the other haematological malignancies. CONCLUSIONS: In summary, a total of six rare myeloid neoplasms may present with a novel immunohistochemical phenomenon tentatively termed TROCI-BM.
机译:目的:骨髓中紧凑的类胰蛋白酶阳性圆形细胞浸润(TROCI-BM)是非常罕见的组织病理学发现,并且可能对涉及的细胞类型(肥大细胞或嗜碱性粒细胞)和确切诊断造成挑战。方法:在总共410例常规处理的骨髓活检标本中,针对肥大细胞和嗜碱性粒细胞相关抗原(包括CD25,CD34,CD117 / Kit和2D7抗原(仅在嗜碱性粒细胞中发现))选择的一组免疫组化标记物(其中包括88例系统性肥大细胞增多症(SM),20例慢性粒细胞白血病(CML),92例除CML以外的骨髓瘤以及210例正常/反应性骨髓对照。结果:总共可鉴定出TROCI-BM 17例:11例SM(包括2例高分化SM和2例肥大细胞白血病; MCL),2例骨髓细胞白血病(MML),2例伴嗜碱性粒细胞过多的CML(继发)嗜碱性粒细胞白血病(CMLba))和2种类胰蛋白酶阳性的急性髓细胞白血病(AML)。关于涉及的细胞类型,发现在所有SM和MCL病例中,TROCI-BM细胞均表达CD117 / Kit。在MML和类胰蛋白酶阳性AML中,发现TROCI-BM细胞共表达CD34和Kit。仅在两名患有CMLba的患者的CD34 / Kit阴性TROCI-BM细胞中检测到了嗜碱性粒细胞特异性抗原2D7。在8/11例SM患者中检测到激活点突变D816V,但在其他任何血液恶性肿瘤中均未检测到。结论:总之,总共可能出现6种罕见的髓样肿瘤,并伴有一种新的免疫组织化学现象,暂定名为TROCI-BM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号